A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

Phase 1

Celldex Therapeutics